JP2021109859A - External skin preparation - Google Patents
External skin preparation Download PDFInfo
- Publication number
- JP2021109859A JP2021109859A JP2020004139A JP2020004139A JP2021109859A JP 2021109859 A JP2021109859 A JP 2021109859A JP 2020004139 A JP2020004139 A JP 2020004139A JP 2020004139 A JP2020004139 A JP 2020004139A JP 2021109859 A JP2021109859 A JP 2021109859A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- mass
- external preparation
- component
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 229940007062 eucalyptus extract Drugs 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract description 10
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract description 8
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 6
- 244000166124 Eucalyptus globulus Species 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 235000004692 Eucalyptus globulus Nutrition 0.000 claims description 6
- LWLHCZLCSDUDEL-UHFFFAOYSA-O C[N+](C)(C)CC(O)=P(=O)CCOC(=O)C=C Chemical compound C[N+](C)(C)CC(O)=P(=O)CCOC(=O)C=C LWLHCZLCSDUDEL-UHFFFAOYSA-O 0.000 claims description 5
- 241000219926 Myrtaceae Species 0.000 claims description 4
- 229920005604 random copolymer Polymers 0.000 claims description 4
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 claims description 3
- 238000004581 coalescence Methods 0.000 claims description 2
- ZIKOEJXVXHYYFQ-UHFFFAOYSA-N trimethyl-[2-(2-methylhept-2-enoyloxy)-2-[2-(2-methylprop-2-enoyloxy)ethyl-oxidophosphaniumylidene]ethyl]azanium Chemical compound C(CCC)C=C(C(=O)OC(C[N+](C)(C)C)=P(=O)CCOC(C(=C)C)=O)C ZIKOEJXVXHYYFQ-UHFFFAOYSA-N 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 abstract description 21
- 229920001577 copolymer Polymers 0.000 abstract description 15
- 230000005808 skin problem Effects 0.000 abstract description 4
- 229950004354 phosphorylcholine Drugs 0.000 abstract description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 27
- 230000001603 reducing effect Effects 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000007803 itching Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- -1 methacryloyl Chemical group 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- SOGAXMICEFXMKE-UHFFFAOYSA-N alpha-Methyl-n-butyl acrylate Natural products CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 229920001083 polybutene Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010012444 Dermatitis diaper Diseases 0.000 description 2
- 208000003105 Diaper Rash Diseases 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000500941 Stackhousia Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000007870 radical polymerization initiator Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は皮膚外用剤に関する。 The present invention relates to an external preparation for skin.
高齢化社会が到来した日本では、介護用のおむつが必要な高齢者が増えてきている。高齢者の皮膚は水分保持能やバリア機能が低下する傾向にあり、皮膚に何かしらのトラブルを抱えている場合がある。特におむつ着用時には蒸れやすく、かゆみなどの皮膚トラブルが起きることがあり、ＱＯＬ（Ｑｕａｌｉｔｙ ｏｆ ｌｉｆｅ）低下の一因になる。健やかな皮膚が維持されるには皮膚の水分量を適切に保つ必要があるため、水分、保湿剤、油剤および植物エキスなどの機能成分が含まれる皮膚外用剤が用いられる。例えば特許文献１は、スタックホウシア科（Ｓｔａｃｋｈｏｕｓｉａｃｅａｅ）に分類される植物の抽出物を含む皮膚外用剤が、保湿性に優れ、肌荒れの改善や予防効果に優れていることを開示している。しかし、引用文献１の皮膚外用剤は、保湿性や肌荒れには有効であるものの、おむつ着用時における対策は不十分だった。
特許文献２は、植物抽出液、有機酸、水を含むことを特徴とする清浄・清拭用及び化粧水用液剤組成物を開示しており、容易に皮膚を清浄および清拭できることで、排泄物等に起因する炎症や、皮膚のかさかさ感の防止が図られている。しかし特許文献２の組成物は、洗浄・清拭による対策は図られているものの、皮膚との摩擦による悪影響があるなど十分でなかった。
おむつ着用時には、着用部周辺の皮膚は蒸れやすく、摩擦により皮膚の状態が悪化しやすい環境にある。しかしながら、おむつ着用部周辺の皮膚に従来の皮膚外用剤を塗布しても、優れた保湿性を与え、おむつ着用時に皮膚トラブルを抑えつつ、滑らかな皮膚に整えることでおむつと皮膚との摩擦を低減することは十分に達成できていなかった。
In Japan, where the aging society has arrived, the number of elderly people who need diapers for long-term care is increasing. The skin of the elderly tends to have reduced water retention and barrier function, and may have some trouble with the skin. Especially when wearing a diaper, it is easy to get stuffy, and skin troubles such as itching may occur, which contributes to a decrease in QOL (Quality of life). Since it is necessary to maintain an appropriate amount of water in the skin in order to maintain healthy skin, external preparations for the skin containing functional ingredients such as water, moisturizers, oils and plant extracts are used. For example, Patent Document 1 discloses that an external preparation for skin containing an extract of a plant classified in the Stackhousia family has excellent moisturizing properties and is excellent in improving and preventing rough skin. However, although the external preparation for skin of Cited Document 1 is effective for moisturizing and rough skin, the countermeasures when wearing a diaper are insufficient.
Patent Document 2 discloses a liquid composition for cleaning / cleaning and lotion containing a plant extract, an organic acid, and water, and excretes the skin by easily cleaning and cleaning the skin. It is designed to prevent inflammation caused by objects and the feeling of bulkiness of the skin. However, although the composition of Patent Document 2 has been cleaned and wiped, it is not sufficient because it has an adverse effect due to friction with the skin.
When wearing a diaper, the skin around the wearing part tends to get stuffy, and the condition of the skin tends to deteriorate due to friction. However, even if a conventional external preparation for skin is applied to the skin around the diaper wearing part, it gives excellent moisturizing properties, suppresses skin troubles when wearing the diaper, and prepares the skin to be smooth so that the friction between the diaper and the skin can be prevented. The reduction was not fully achieved.
本発明の目的は、おむつ着用部周辺の皮膚に塗布することで、優れた保湿性を与え、皮膚トラブルを起こしにくく、おむつと皮膚との摩擦が低減できる皮膚外用剤を提供することにある。 An object of the present invention is to provide an external preparation for skin that, when applied to the skin around a diaper wearing portion, provides excellent moisturizing properties, is less likely to cause skin troubles, and can reduce friction between the diaper and the skin.
本発明者らは、後述の成分（ａ）〜（ｃ）を特定の割合で配合することで上記課題を解決することを見出して本発明を完成させた。
すなわち、本発明は、次の通りである。
（ａ）平均分子量が８００〜３０００の炭化水素油を０．５質量％〜１０質量％、
（ｂ）下記式（１）で表される２−（メタ）アクリロイルオキシエチルホスホリルコリンに基づく構成単位、および下記式（２）で表される（メタ）アクリル酸アルキルに基づく構成単位を含む共重合体を０．００５質量％〜０．５質量％、および、
（ｃ）フトモモ科ユーカリ属植物であるユーカリプタス・グロブラス（Ｅｕｃａｌｙｐｔｕｓ ｇｌｏｂｕｌｕｓ）より得られるユーカリ抽出物を、有効成分として０．００１質量％〜０．１質量％含有する皮膚外用剤。
The present inventors have found that the above problems can be solved by blending the components (a) to (c) described below in a specific ratio, and have completed the present invention.
That is, the present invention is as follows.
(A) Hydrocarbon oil having an average molecular weight of 800 to 3000 is 0.5% by mass to 10% by mass,
(B) Coweight containing a structural unit based on 2- (meth) acryloyloxyethyl phosphorylcholine represented by the following formula (1) and a structural unit based on alkyl (meth) acrylate represented by the following formula (2). The coalescence is 0.005% by mass to 0.5% by mass, and
(C) An external preparation for skin containing 0.001% by mass to 0.1% by mass of an eucalyptus extract obtained from Eucalyptus globulus, which is a plant belonging to the genus Eucalyptus of the Myrtaceae family, as an active ingredient.
（式中、Ｒ１は水素原子またはメチル基を示す。） (In the formula, R 1 represents a hydrogen atom or a methyl group.)
（式中、Ｒ２は水素原子またはメチル基を示し、Ｒ３は炭素数４〜１８のアルキル基を示す。） (In the formula, R 2 represents a hydrogen atom or a methyl group, and R 3 represents an alkyl group having 4 to 18 carbon atoms.)
本発明の皮膚外用剤は、おむつ着用部周辺の皮膚に塗布することで、優れた保湿性を与え、皮膚トラブルを起こしにくく、皮膚とおむつとの摩擦が低減できる。 By applying the external preparation for skin of the present invention to the skin around the diaper wearing part, excellent moisturizing property is given, skin troubles are less likely to occur, and friction between the skin and the diaper can be reduced.
以下、本発明の実施形態を説明する。本発明の皮膚外用剤は、下記成分（ａ）、成分（ｂ）、成分（ｃ）を含有する。以下、各成分について説明する。
（ａ）平均分子量が８００〜３０００の炭化水素油
（ｂ）下記式（１）で表される２−（メタ）アクリロイルオキシエチルホスホリルコリンに基づく構成単位、および下記式（２）で表される（メタ）アクリル酸アルキルに基づく構成単位を含む共重合体
Hereinafter, embodiments of the present invention will be described. The external preparation for skin of the present invention contains the following component (a), component (b), and component (c). Hereinafter, each component will be described.
(A) Hydrocarbon oil having an average molecular weight of 800 to 3000 (b) A structural unit based on 2- (meth) acryloyloxyethyl phosphorylcholine represented by the following formula (1), and represented by the following formula (2) ( Meta) Copolymers containing structural units based on alkyl acrylates
（式中、Ｒ１は水素原子またはメチル基を示す。） (In the formula, R 1 represents a hydrogen atom or a methyl group.)
（式中、Ｒ２は水素原子またはメチル基を示し、Ｒ３は炭素数４〜１８のアルキル基を示す。） (In the formula, R 2 represents a hydrogen atom or a methyl group, and R 3 represents an alkyl group having 4 to 18 carbon atoms.)
（ｃ）フトモモ科ユーカリ属植物であるユーカリプタス・グロブラス（Ｅｕｃａｌｙｐｔｕｓ ｇｌｏｂｕｌｕｓ）より得られるユーカリ抽出物 (C) Eucalyptus extract obtained from Eucalyptus globulus, a plant belonging to the genus Eucalyptus in the family Myrtaceae.
〔成分（ａ）〕
本発明に用いられる成分（ａ）は、平均分子量が８００〜３０００の炭化水素油であり、炭化水素化合物の混合物であって、その平均分子量が８００〜３０００のものだけでなく、分子量が８００〜３０００である単独の炭化水素化合物も含まれる。例えば、平均分子量が８００〜３０００のポリブテン、平均分子量が８００〜３０００の水添ポリイソブテン等が挙げられ、好ましくは平均分子量が８００〜３０００の水添ポリイソブテンである。
炭化水素油の平均分子量は、好ましくは９００〜２９００であり、より好ましくは１０００〜２８００である。平均分子量が低すぎると、保湿性、皮膚トラブル改善効果および皮膚との摩擦低減効果が不十分となることがあり、平均分子量（又は分子量）が高すぎると、べたつき感が生じるため、皮膚との摩擦低減効果が悪化することがある。なお、炭化水素油の平均分子量は、ゲル浸透クロマトグラフィー（ＧＰＣ）により、ポリエチレングリコール換算で求めた数平均分子量である。
炭化水素油は、市販の製品を用いることもできる。例えば、平均分子量が８００〜３０００の水添ポリイソブテンとしては、登録商標パールリーム１８（平均分子量：１０００）、登録商標パールリーム２４（平均分子量：１３５０）、登録商標パールリーム４６（平均分子量：２６５０）（いずれも日油株式会社製）等が挙げられる。
本発明において、成分（ａ）の含有量は、皮膚外用剤中に、０．５〜１０質量％であり、１〜８質量％が好ましく、さらに２〜４質量％がより好ましい。成分（ａ）の含有量が０．５質量％を下回ると、保湿性、皮膚トラブル改善効果および皮膚との摩擦低減効果が不十分となる。一方、成分（ａ）の含有量が１０質量％を超える場合は、べたつき感が生じてしまい、皮膚との摩擦低減効果が低下する。
[Component (a)]
The component (a) used in the present invention is a hydrocarbon oil having an average molecular weight of 800 to 3000, and is a mixture of hydrocarbon compounds having an average molecular weight of 800 to 3000 as well as a molecular weight of 800 to 3000. Also included is a single hydrocarbon compound of 3000. For example, polybutene having an average molecular weight of 800 to 3000, hydrogenated polybutene having an average molecular weight of 800 to 3000, and the like can be mentioned, and hydrogenated polybutene having an average molecular weight of 800 to 3000 is preferable.
The average molecular weight of the hydrocarbon oil is preferably 900 to 2900, more preferably 1000 to 2800. If the average molecular weight is too low, the moisturizing property, the effect of improving skin troubles, and the effect of reducing friction with the skin may be insufficient, and if the average molecular weight (or molecular weight) is too high, a sticky feeling occurs. The friction reduction effect may deteriorate. The average molecular weight of the hydrocarbon oil is a number average molecular weight obtained in terms of polyethylene glycol by gel permeation chromatography (GPC).
Commercially available products can also be used as the hydrocarbon oil. For example, as hydrogenated polyisobutene having an average molecular weight of 800 to 3000, the registered trademark Pearl Dream 18 (average molecular weight: 1000), the registered trademark Pearl Dream 24 (average molecular weight: 1350), and the registered trademark Pearl Dream 46 (average molecular weight: 2650) (Both manufactured by Nichiyu Co., Ltd.) and the like.
In the present invention, the content of the component (a) is 0.5 to 10% by mass, preferably 1 to 8% by mass, and more preferably 2 to 4% by mass in the external preparation for skin. When the content of the component (a) is less than 0.5% by mass, the moisturizing property, the effect of improving skin troubles, and the effect of reducing friction with the skin become insufficient. On the other hand, when the content of the component (a) exceeds 10% by mass, a sticky feeling occurs and the effect of reducing friction with the skin is reduced.
〔成分（ｂ）〕
本発明に用いられる成分（ｂ）は、下記の式（１）および式（２）で表される構成単位を含む共重合体である。
[Component (b)]
The component (b) used in the present invention is a copolymer containing a structural unit represented by the following formulas (1) and (2).
（式中、Ｒ１は水素原子またはメチル基を示す。） (In the formula, R 1 represents a hydrogen atom or a methyl group.)
（式中、Ｒ２は水素原子またはメチル基を示し、Ｒ３は炭素数４〜１８のアルキル基を示す。） (In the formula, R 2 represents a hydrogen atom or a methyl group, and R 3 represents an alkyl group having 4 to 18 carbon atoms.)
上記式（１）で示される構成単位は、２−（メタ）アクリロイルオキシエチルホスホリルコリンに基づく構成単位である。ここで、「（メタ）アクリロイル」とは、「アクリロイルまたはメタクリロイル」を意味する。
また、上記式（２）で示される構成単位は、（メタ）アクリル酸アルキルに基づく構成単位である。ここで、「（メタ）アクリル酸」とは「アクリル酸またはメタクリル酸」を意味する。（メタ）アクリル酸アルキルにおけるアルキル基は、炭素数４〜１８の直鎖または分岐のアルキル基であり、ブチル、ペンチル、ヘキシル、オクチル、２−エチルヘキシル、デシル、ドデシル、テトラデシル、ヘキサデシル、オクタデシル等が例示される。なかでも、ブチル、ドデシル、オクタデシル等の直鎖アルキル基が好ましく、ブチル基またはオクタデシル基（別名ステアリル基）がより好ましい。
なお、上記アルキル基の炭素数が小さ過ぎる場合には、本発明の効果を低減せしめる場合がある。また上記アルキル基の炭素数が大き過ぎる場合には、水や水性溶媒への溶解が困難になる場合がある。
The structural unit represented by the above formula (1) is a structural unit based on 2- (meth) acryloyloxyethyl phosphorylcholine. Here, "(meth) acryloyl" means "acryloyl or methacryloyl".
The structural unit represented by the above formula (2) is a structural unit based on alkyl (meth) acrylate. Here, "(meth) acrylic acid" means "acrylic acid or methacrylic acid". The alkyl group in the alkyl (meth) acrylate is a linear or branched alkyl group having 4 to 18 carbon atoms, such as butyl, pentyl, hexyl, octyl, 2-ethylhexyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl and the like. Illustrated. Of these, a linear alkyl group such as butyl, dodecyl, or octadecyl is preferable, and a butyl group or an octadecyl group (also known as a stearyl group) is more preferable.
If the number of carbon atoms of the alkyl group is too small, the effect of the present invention may be reduced. If the alkyl group has too many carbon atoms, it may be difficult to dissolve it in water or an aqueous solvent.
式（１）で示される構成単位の量をｎ１、および、式（２）で示される構成単位の量をｎ２としたときに、上記式（１）で示される構成単位と、上記式（２）で示される構成単位の共重合体中におけるそれぞれの含有量の比（ｎ１：ｎ２）は、モル比にて１０：１〜１：５であり、好ましくは７：１〜１：４であり、より好ましくは５：１〜１：３である。式（１）で示される構成単位の含有量に対する式（２）で示される構成単位の含有量の比（ｎ２／ｎ１）（モル比）が０．１未満である場合には、おむつかぶれ改善効果やおむつ交換のしやすさが低下するおそれがある。一方、前記比が５を超えると、保湿性や皮膚トラブル改善効果が低下するおそれがある。 When the amount of the structural unit represented by the formula (1) is n1 and the amount of the structural unit represented by the formula (2) is n2, the structural unit represented by the above formula (1) and the above formula (2) The ratio (n1: n2) of each content of the structural unit represented by () in the copolymer is 10: 1 to 1: 5 in terms of molar ratio, preferably 7: 1 to 1: 4. , More preferably 5: 1 to 1: 3. When the ratio (n2 / n1) (molar ratio) of the content of the structural unit represented by the formula (2) to the content of the structural unit represented by the formula (1) is less than 0.1, the diaper rash is improved. The effect and ease of changing diapers may decrease. On the other hand, if the ratio exceeds 5, the moisturizing property and the effect of improving skin troubles may decrease.
成分（ｂ）である共重合体の重量平均分子量は、通常１０，０００〜１，０００，０００であり、好ましくは３０，０００〜９００，０００であり、さらに好ましくは５０，０００〜８００，０００である。共重合体の重量平均分子量が１０，０００未満である場合には、保湿性、皮膚トラブル改善効果、皮膚との摩擦低減効果を損なう可能性があり、一方、共重合体の重量平均分子量が１，０００，０００を超える場合には、取り扱いが困難となるおそれがある。なお、共重合体Ｂの重量平均分子量は、ゲル浸透クロマトグラフィー（ＧＰＣ）によって測定され、ポリエチレングリコール換算の分子量で示される。 The weight average molecular weight of the copolymer as the component (b) is usually 10,000 to 1,000,000, preferably 30,000 to 900,000, and more preferably 50,000 to 800,000. Is. When the weight average molecular weight of the copolymer is less than 10,000, the moisturizing property, the effect of improving skin troubles, and the effect of reducing friction with the skin may be impaired, while the weight average molecular weight of the copolymer is 1. If it exceeds 000,000, it may be difficult to handle. The weight average molecular weight of the copolymer B is measured by gel permeation chromatography (GPC) and is shown by the molecular weight in terms of polyethylene glycol.
共重合体の重合形態は特に限定されず、ランダム共重合体であっても、ブロック共重合体であってもよいが、ランダム共重合体が好ましい。
共重合体が上記式（１）または式（２）で示される構成単位以外の構成単位を含む場合には、共重合体中における他の構成単位の含有量は４０モル％以下であり、好ましくは２０モル％以下である。
The polymerization form of the copolymer is not particularly limited, and it may be a random copolymer or a block copolymer, but a random copolymer is preferable.
When the copolymer contains a structural unit other than the structural unit represented by the above formula (1) or the formula (2), the content of the other structural unit in the copolymer is preferably 40 mol% or less. Is less than 20 mol%.
共重合体は、公知の製造方法により製造することができる。例えば、２−（メタ）アクリロイルオキシエチルホスホリルコリンおよび（メタ）アクリル酸アルキル、ならびに必要に応じて上記他の構成単位に相当する単量体を含む単量体混合物を、ラジカル重合開始剤の存在下、窒素等の不活性ガス雰囲気下において、溶液重合等の公知の方法により重合させて製造することができる。
その際の各単量体の仕込み量比は、成分（ｂ）である共重合体中における各構成単位の含有量比に相当する比とすればよい。本発明の皮膚外用剤には、成分（ｂ）である共重合体を１種のみ単独で、または２種以上を組み合わせて含有させることができる。
共重合体は、上記した重合方法により製造して用いることもできるが、「リピジュア（登録商標）−Ｂ」、「リピジュア（登録商標）−ＰＭＢ」、「リピジュア（登録商標）−ＮＲ」（日油株式会社製）等の市販の製品を用いることもできる。
The copolymer can be produced by a known production method. For example, a monomer mixture containing 2- (meth) acryloyloxyethyl phosphorylcholine and alkyl (meth) acrylate, and optionally a monomer corresponding to the other structural unit, in the presence of a radical polymerization initiator. It can be produced by polymerization in an atmosphere of an inert gas such as nitrogen by a known method such as solution polymerization.
At that time, the charging amount ratio of each monomer may be a ratio corresponding to the content ratio of each structural unit in the copolymer which is the component (b). The external preparation for skin of the present invention may contain the copolymer as the component (b) alone or in combination of two or more.
The copolymer can be produced and used by the above-mentioned polymerization method, but "Lipidure (registered trademark) -B", "Lipidure (registered trademark) -PMB", "Lipidure (registered trademark) -NR" (Japan). Commercially available products such as (manufactured by NOF CORPORATION) can also be used.
本発明において、成分（ｂ)の含有量は、皮膚外用剤中に、０．００５〜０．５質量％であり、０．０１〜０．４質量％が好ましく、さらに０．０２〜０．３質量％がより好ましい。成分（ｂ）の含有率が０．００５質量％を下回ると、保湿性、皮膚トラブル改善効果、皮膚との摩擦低減効果が不十分となることがあり、０．５質量％を超える場合は、配合量に見合った効果が得られない。 In the present invention, the content of the component (b) is 0.005 to 0.5% by mass, preferably 0.01 to 0.4% by mass, and further 0.02 to 0. 3% by mass is more preferable. If the content of the component (b) is less than 0.005% by mass, the moisturizing property, the effect of improving skin troubles, and the effect of reducing friction with the skin may be insufficient. The effect commensurate with the blending amount cannot be obtained.
〔成分（ｃ）〕
本発明に用いられる成分（ｃ）は、ユーカリ抽出物であり、フトモモ科ユーカリ属植物であるユーカリプタス・グロブラス（Ｅｕｃａｌｙｐｔｕｓ ｇｌｏｂｕｌｕｓ）およびその近縁種よりなる群から選ばれる少なくとも一つのユーカリ属植物から得られるものである。
ユーカリ抽出液の製造に用いる植物体の部位としては、葉が好ましく、特に萌芽から３年以内の枝につく幼葉が保湿性、皮膚トラブル改善効果および皮膚との摩擦低減効果の面でより好ましい。幼葉は、対生で、卵形であり、白い粉を吹いたような表面をしている。一方、成葉は、互生で、披針形であり、全縁（葉の縁がなめらか）である。したがって、ユーカリプタス・グロブラスおよびその近縁種の幼葉と成葉は外見上、明確に区別が可能である。
ユーカリプタス・グロブラスおよびその近縁種の葉を原料として溶媒抽出することによって、本発明で用いられるユーカリ抽出液が得られる。ユーカリ抽出液を得るために溶媒抽出する際は、生葉をそのままで溶媒抽出しても良いが、抽出効率を考えると、生細切、乾燥、粉砕等の処理を行った後に溶媒抽出を行うことが好ましい。
抽出に使用する溶媒としては、例えば、水、エタノール、プロパノール、イソプロパノール等の低級アルコール、１，３−ブチレングリコール、プロピレングリコール、ジプロピレングリコール，グリセリン等の多価アルコール、エチルエーテル、プロピルエーテル等のエーテル、酢酸エチル、酢酸ブチル等のエステル、アセトン、エチルメチルケトン等のケトンなどの極性有機溶媒を用いることができる。また、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等を用いても良い。これら溶媒のうち１種を単独で使用しても良く、また２種以上の混合物を使用しても良い。
これら溶媒のなかでも、水、エタノール、プレピレングリコール、１，３−ブチレングリコールから選ばれる１種または２種以上の混合物を使用することが好ましく、より好ましくはエタノールと水の混合物である。
[Component (c)]
The component (c) used in the present invention is a eucalyptus extract obtained from at least one eucalyptus plant selected from the group consisting of Eucalyptus globulus, which is a plant of the genus Eucalyptus of the family Myrtaceae, and related species thereof. Is something that can be done.
As the part of the plant used for producing the eucalyptus extract, leaves are preferable, and young leaves attached to branches within 3 years from sprouting are more preferable in terms of moisturizing property, skin trouble improving effect and friction reducing effect with skin. .. The young leaves are opposite, oval, and have a white powder-like surface. Adult leaves, on the other hand, are alternate, lanceolate, and have full edges (smooth leaf edges). Therefore, the young and mature leaves of Eucalyptus globulus and its related species are apparently clearly distinguishable.
The eucalyptus extract used in the present invention can be obtained by solvent-extracting the leaves of eucalyptus globulus and its closely related species as raw materials. When solvent-extracting to obtain a eucalyptus extract, the fresh leaves may be extracted as they are, but considering the extraction efficiency, the solvent should be extracted after performing treatments such as raw shredding, drying, and crushing. Is preferable.
Examples of the solvent used for extraction include water, lower alcohols such as ethanol, propanol and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol and glycerin, ethyl ether and propyl ether. Polar organic solvents such as ether, esters such as ethyl acetate and butyl acetate, and ketones such as acetone and ethyl methyl ketone can be used. Further, physiological saline, phosphate buffer, phosphate buffered saline and the like may be used. One of these solvents may be used alone, or a mixture of two or more may be used.
Among these solvents, it is preferable to use one or a mixture of two or more selected from water, ethanol, prepyrene glycol, and 1,3-butylene glycol, and more preferably a mixture of ethanol and water.
成分（ｃ）としては、上記溶媒抽出により得られたユーカリ抽出液を、そのままでも本発明の皮膚外用剤に含有させることができ、また得られたユーカリ抽出液に様々な処理を行なったものを本発明の皮膚外用剤に含有させることができる。例えば、抽出液を希釈した希釈液；抽出液を濃縮、乾固または凍結乾燥して得られた濃縮液、ペーストまたは粉末；得られた濃縮液、ペースト、粉末を水や有機極性溶媒で希釈あるいは溶解した希釈液、溶液；あるいは効果を損なわない範囲で脱色、脱臭、脱塩等の精製処理を行った精製物；カラムクロマトグラフィ等による分画処理を行った処理物などを本発明の皮膚外用剤に含有させることができる。また、ユーカリ抽出物をリポソーム等のベシクルやマイクロカプセル等に内包させて用いることもできる。 As the component (c), the eucalyptus extract obtained by the above solvent extraction can be contained in the skin external preparation of the present invention as it is, and the obtained eucalyptus extract is subjected to various treatments. It can be contained in the external preparation for skin of the present invention. For example, a diluted solution obtained by diluting the extract; a concentrate obtained by concentrating, drying or freeze-drying the extract, a paste or powder; the obtained concentrate, paste, powder is diluted with water or an organic polar solvent, or Dissolved diluents and solutions; or purified products that have been subjected to purification treatments such as decolorization, deodorization, and desalting within the range that does not impair the effects; Can be contained in. Further, the eucalyptus extract can be used by being encapsulated in vesicles such as liposomes or microcapsules.
成分（ｃ）の含有量は、皮膚外用剤中に、ユーカリ抽出物を有効成分（ユーカリ抽出液の乾燥残留物の質量に換算した値）として０．００１〜０．１質量％であり、好ましくは０．０１〜０．０８質量％、より好ましくは０．０２〜０．０６質量％である。成分（ｃ）の含有量が有効成分として０．０００１質量％未満であると、保湿性、皮膚トラブル改善効果、皮膚との摩擦低減効果が低下するおそれがあり、また、１質量％を超えると、配合に見合った効果が得られない。
本発明における乾燥残留物とは、通常、抽出液を１０５℃で乾燥するか、または減圧乾固して溶媒を除去したときの残留物である溶質をいう。なお、抽出溶媒が不揮発性である場合には、ガスクロマトグラフィ、高速クロマトグラフィなどにより溶媒量を定量した値から、溶質量を算出し、乾燥残留物量とみなすことができる。
The content of the component (c) is preferably 0.001 to 0.1% by mass, with the eucalyptus extract as the active ingredient (value converted to the mass of the dry residue of the eucalyptus extract) in the external preparation for skin. Is 0.01 to 0.08% by mass, more preferably 0.02 to 0.06% by mass. If the content of the component (c) is less than 0.0001% by mass as the active ingredient, the moisturizing property, the effect of improving skin troubles, and the effect of reducing friction with the skin may be lowered, and if it exceeds 1% by mass. , The effect commensurate with the formulation cannot be obtained.
The dry residue in the present invention usually refers to a solute which is a residue when the extract is dried at 105 ° C. or dried under reduced pressure to remove the solvent. When the extraction solvent is non-volatile, the dissolved mass can be calculated from the value obtained by quantifying the amount of the solvent by gas chromatography, high-speed chromatography, or the like, and can be regarded as the amount of dry residue.
本発明の皮膚外用剤には、本発明の効果を阻害しない範囲内で、上記の成分（ａ）〜成分（ｃ）以外の他の成分を含有させることができる。他の成分は外用剤や化粧料等に常用されるものであり、例えば、エタノールなどの低級アルコール、プロピレングリコールなどのジオール類、糖アルコールおよび糖アルコール誘導体、カルボキシビニルポリマーなどの増粘剤、糖類、界面活性剤、有機塩、無機塩、ｐＨ調整剤、キレート剤、抗酸化剤、殺菌剤、血流促進剤、抗炎症剤、紫外線吸収剤、紫外線散乱剤、ビタミン類、アルギニンなどのアミノ酸、色素、香料などが挙げられ、本発明の性能を損なわない範囲で配合することができる。 The external preparation for skin of the present invention may contain components other than the above-mentioned components (a) to (c) as long as the effects of the present invention are not impaired. Other components are commonly used in external preparations, cosmetics, etc., for example, lower alcohols such as ethanol, diols such as propylene glycol, sugar alcohols and sugar alcohol derivatives, thickeners such as carboxyvinyl polymers, and sugars. , Surfactants, organic salts, inorganic salts, pH adjusters, chelating agents, antioxidants, bactericides, blood flow promoters, anti-inflammatory agents, UV absorbers, UV scatterers, vitamins, amino acids such as arginine, Examples thereof include dyes and fragrances, which can be blended within a range that does not impair the performance of the present invention.
本発明の皮膚外用剤の剤型としては特に制限されず、ローション剤や乳液等の液剤であってもよく、クリーム、ジェルなど半固形状であってもよく、皮膚に塗布可能な剤型であればその他の剤型であってもよい。 The dosage form of the external preparation for skin of the present invention is not particularly limited, and may be a liquid preparation such as a lotion or a milky lotion, or may be a semi-solid form such as a cream or gel, and is a dosage form that can be applied to the skin. If there is, other dosage forms may be used.
以下に実施例および比較例を挙げて本発明をさらに詳細に説明する。
〔実施例１〜７、比較例１〜３〕
実施例１〜７および比較例１〜３の皮膚外用剤を調製し、得られた各皮膚外用剤について評価を行った。実施例１〜７の組成および評価結果を表１に示し、比較例１〜３の組成および評価結果を表２に示す。
Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples.
[Examples 1 to 7, Comparative Examples 1 to 3]
The skin external preparations of Examples 1 to 7 and Comparative Examples 1 to 3 were prepared, and each of the obtained skin external preparations was evaluated. The compositions and evaluation results of Examples 1 to 7 are shown in Table 1, and the compositions and evaluation results of Comparative Examples 1 to 3 are shown in Table 2.
＜皮膚外用剤の調製＞
実施例１〜７については各成分を表１に示す配合割合（質量％）で配合し、また、比較例１〜３については各成分を表２に示す配合割合（質量％）で配合し、以下の方法により皮膚外用剤を調製した。
すなわち、油相として成分（ａ）および共通成分３〜１１、水相として共通成分１、２、１２をそれぞれ混合し、７５℃〜８０℃に加熱し、ホモミキサーを用いて混合した後に、４０℃以下に冷却し、さらに成分（ｂ）および成分（ｃ）を混合して皮膚外用剤を得た。成分（ｃ）であるユーカリ抽出液の含有量は有効成分の質量として示す。
表１中の成分は次のとおりである。
・成分（ａ）：日油株式会社製、パールリーム２４（登録商標）
水添ポリイソブテン、平均分子量１３５０
・成分（ｂ）：日油株式会社製、リピジュア（登録商標）−ＰＭＢ（Ph10）
（２−メタアクリロイルオキシエチルホスホリルコリン）−（ブチル−メタクリレート）ランダム共重合体、
式（１）の単位（２−メタアクリロイルオキシエチルホスホリルコリン）の含有量（ｎ１）と式（１）の単位（ブチル−メタクリレート）の含有量（ｎ２）のモル比（ｎ１：ｎ２）が４：１、重量平均分子量が約６０万、
・成分（ｃ）：日油株式会社製、ユーカリエキスＢＧ（製品名）
ユーカリ抽出液（有効成分：１．０質量％）
・共通成分：表３に示す各成分（配合比率を質量部で示す。）
<Preparation of external preparation for skin>
In Examples 1 to 7, each component was blended in the blending ratio (mass%) shown in Table 1, and in Comparative Examples 1 to 3, each component was blended in the blending ratio (mass%) shown in Table 2. An external preparation for skin was prepared by the following method.
That is, the component (a) and the common components 3 to 11 as the oil phase and the common components 1, 2 and 12 as the aqueous phase are mixed, heated to 75 ° C to 80 ° C, mixed using a homomixer, and then 40. After cooling to ° C. or lower, the component (b) and the component (c) were further mixed to obtain an external preparation for skin. The content of the eucalyptus extract as the component (c) is shown as the mass of the active ingredient.
The components in Table 1 are as follows.
-Ingredient (a): Made by NOF CORPORATION, Pearl Dream 24 (registered trademark)
Hydrogenated polyisobutene, average molecular weight 1350
-Ingredient (b): NOF CORPORATION, Lipidure (registered trademark) -PMB (Ph10)
(2-Metaacryloyloxyethyl phosphorylcholine)-(butyl-methacrylate) random copolymer,
The molar ratio (n1: n2) of the content (n1) of the unit (2-methacryloyloxyethyl phosphorylcholine) of the formula (1) to the content (n2) of the unit (butyl-methacrylate) of the formula (1) is 4: 1. Weight average molecular weight is about 600,000,
-Ingredient (c): Eucalyptus extract BG (product name) manufactured by NOF CORPORATION
Eucalyptus extract (active ingredient: 1.0% by mass)
-Common ingredients: Each ingredient shown in Table 3 (the compounding ratio is shown in parts by mass)
＜評価方法＞
（１）保湿性の評価
医療・介護施設などに入所し、おむつを使用することがある６０歳から８０歳の男女２０人をパネラーとした。パネラーは敏感肌でかゆみなどの皮膚トラブルが起きやすいことを申告した方に限定した。パネラーは、皮膚外用剤３ｇをおむつ装着部周辺の皮膚に十分に馴染ませて１時間後に、保湿性について下記のように判定し、採点を行った。
２点：保湿感を十分に感じる場合。
１点：保湿感をやや感じる場合。
０点：保湿感を感じない場合。
パネラー２０名の合計点を求めて、下記の基準で評価した。表に評価結果と合計点を表示した。
◎：合計点が３５点以上かつ０点の評価をしたパネラーがいない。
○：合計点が３０点以上３５点未満かつ０点の評価をしたパネラーがいない。
△：合計点が２０点以上３０点未満、または、合計点が３０点以上かつ０点の評価をしたパネラーがいる。
×：合計点が２０点未満である。
<Evaluation method>
(1) Evaluation of moisturizing properties Twenty men and women aged 60 to 80 who may use diapers after entering medical / nursing facilities were selected as panelists. Panelists were limited to those who reported that they had sensitive skin and were prone to skin problems such as itching. One hour after the paneler sufficiently applied 3 g of the external preparation for skin to the skin around the diaper wearing portion, the moisturizing property was judged as follows and scored.
2 points: When you feel a sufficient moisturizing feeling.
1 point: When you feel a little moisturizing.
0 points: If you do not feel moisturized.
The total score of 20 panelists was calculated and evaluated according to the following criteria. The evaluation results and total points are displayed in the table.
⊚: There is no panelist who evaluated the total score as 35 points or more and 0 points.
◯: There is no panelist who evaluated the total score as 30 points or more and less than 35 points and 0 points.
Δ: There is a panelist who has a total score of 20 points or more and less than 30 points, or a total score of 30 points or more and 0 points.
X: The total score is less than 20 points.
（２）皮膚トラブル改善効果の評価
医療・介護施設などに入所し、おむつを使用することがある６０歳から８０歳の男女２０人をパネラーとした。パネラーは敏感肌でかゆみなどの皮膚トラブルが起きやすいことを申告した方に限定した。パネラーは、皮膚外用剤３ｇを毎日一回おむつ装着部周辺の皮膚に十分に馴染ませた。パネラーは、連続使用して７日目、おむつかぶれ改善効果について下記のように判定し、採点を行った。
２点：かゆみが優位に改善したと感じる場合。
１点：かゆみがやや改善したと感じる場合。
０点：かゆみがあまり変わらないと感じる場合。
パネラー２０名の合計点を求めて、下記の基準で評価した。表に評価結果と合計点を表示した。
◎：合計点が３５点以上かつ０点の評価をしたパネラーがいない。
○：合計点が３０点以上３５点未満かつ０点の評価をしたパネラーがいない。
△：合計点が２０点以上３０点未満、または、合計点が３０点以上かつ０点の評価をしたパネラーがいる。
×：合計点が２０点未満である。
(2) Evaluation of skin trouble improvement effect Twenty men and women aged 60 to 80 who may use diapers after entering medical / nursing facilities were selected as panelists. Panelists were limited to those who reported that they had sensitive skin and were prone to skin problems such as itching. The panelist applied 3 g of the external preparation for skin to the skin around the diaper wearing part once a day. On the 7th day of continuous use, the panelists judged the diaper rash improvement effect as follows and scored.
2 points: When you feel that itching has improved significantly.
1 point: If you feel that the itch has improved a little.
0 points: If you feel that the itch does not change much.
The total score of 20 panelists was calculated and evaluated according to the following criteria. The evaluation results and total points are displayed in the table.
⊚: There is no panelist who evaluated the total score as 35 points or more and 0 points.
◯: There is no panelist who evaluated the total score as 30 points or more and less than 35 points and 0 points.
Δ: There is a panelist who has a total score of 20 points or more and less than 30 points, or a total score of 30 points or more and 0 points.
X: The total score is less than 20 points.
（３）皮膚との摩擦低減効果の評価
医療・介護施設などに入所し、おむつを使用することがある６０歳から８０歳の男女２０人をパネラーとした。パネラーは敏感肌でかゆみなどの皮膚トラブルが起きやすいことを申告した方に限定した。パネラーは、皮膚外用剤３ｇを毎日一回おむつ装着部周辺の皮膚に十分に馴染ませた。パネラーは、連続使用して７日目、皮膚との摩擦低減効果について下記のように判定し、採点を行った。
２点：皮膚が滑らかになりおむつとの摩擦が低減したと感じた場合。
１点：皮膚が滑らかになりおむつとの摩擦がやや低減したと感じた場合。
０点：おむつとの摩擦が変わらないと感じた場合。
パネラー２０名の合計点を求めて、下記の基準で評価した。表に評価結果と合計点を表示した。
◎：合計点が３５点以上かつ０点の評価をしたパネラーがいない。
○：合計点が３０点以上３５点未満かつ０点の評価をしたパネラーがいない。
△：合計点が２０点以上３０点未満、または、合計点が３０点以上かつ０点の評価をしたパネラーがいる。
×：合計点が２０点未満である。
(3) Evaluation of the effect of reducing friction with the skin Twenty men and women aged 60 to 80 who may use diapers after entering medical / nursing facilities were selected as panelists. Panelists were limited to those who reported that they had sensitive skin and were prone to skin problems such as itching. The panelist applied 3 g of the external preparation for skin to the skin around the diaper wearing part once a day. On the 7th day of continuous use, the panelists judged the effect of reducing friction with the skin as follows and scored.
2 points: When you feel that the skin is smooth and the friction with the diaper is reduced.
1 point: When you feel that the skin is smooth and the friction with the diaper is slightly reduced.
0 point: When you feel that the friction with the diaper does not change.
The total score of 20 panelists was calculated and evaluated according to the following criteria. The evaluation results and total points are displayed in the table.
⊚: There is no panelist who evaluated the total score as 35 points or more and 0 points.
◯: There is no panelist who evaluated the total score as 30 points or more and less than 35 points and 0 points.
Δ: There is a panelist who has a total score of 20 points or more and less than 30 points, or a total score of 30 points or more and 0 points.
X: The total score is less than 20 points.
＜評価結果＞
表１に示されるように、実施例１〜７の各皮膚外用剤は、保湿性の向上および皮膚トラブル改善効果に優れ、皮膚とおむつとの摩擦が低減する皮膚外用剤と評価された。
一方、表２に示されるように、比較例１〜３の皮膚外用剤については、以下のとおり、すべての評価項目おいて十分な有効性の認められたものは見られなかった。
例えば成分（ａ）を含有していない比較例１の皮膚外用剤は、皮膚トラブル改善効果および皮膚との摩擦低減効果が不十分であると評価された。
成分（ｂ）を含有していない比較例２の皮膚外用剤は、保湿性および皮膚との摩擦低減効果が不十分であると評価された。
成分（ｃ）を含有していない比較例３の皮膚外用剤は、皮膚トラブル改善効果および皮膚との摩擦低減効果が不十分であると評価された。
<Evaluation result>
As shown in Table 1, each of the external preparations for skin of Examples 1 to 7 was evaluated as an external preparation for skin which is excellent in improving moisturizing property and improving skin troubles and reducing friction between the skin and the diaper.
On the other hand, as shown in Table 2, with respect to the external preparations for skin of Comparative Examples 1 to 3, no one was found to have sufficient efficacy in all the evaluation items as follows.
For example, the external preparation for skin of Comparative Example 1 containing no component (a) was evaluated to have insufficient effects of improving skin troubles and reducing friction with the skin.
The external preparation for skin of Comparative Example 2 containing no component (b) was evaluated to have insufficient moisturizing property and effect of reducing friction with the skin.
The external preparation for skin of Comparative Example 3 containing no component (c) was evaluated to have insufficient skin trouble improving effect and friction reducing effect with the skin.
以上、詳述したように、本発明の皮膚外用剤を、おむつ着用部周辺の皮膚に塗布することで、優れた保湿性を与え、皮膚トラブルを起こしにくく、おむつと皮膚との摩擦が低減できるため、介護用のおむつが必要な高齢者にとっては、おむつ着用部周辺の皮膚の健康状態を維持または改善するために、好適に用いることができる。 As described in detail above, by applying the external skin preparation of the present invention to the skin around the diaper wearing part, excellent moisturizing property is given, skin troubles are less likely to occur, and friction between the diaper and the skin can be reduced. Therefore, for elderly people who need a diaper for long-term care, it can be suitably used for maintaining or improving the health condition of the skin around the diaper wearing part.
Claims (4)
（ｂ）下記式（１）で表される２−（メタ）アクリロイルオキシエチルホスホリルコリンに基づく構成単位、および下記式（２）で表される（メタ）アクリル酸アルキルに基づく構成単位を含む共重合体を０．００５質量％〜０．５質量％、および、
（ｃ）フトモモ科ユーカリ属植物であるユーカリプタス・グロブラス（Ｅｕｃａｌｙｐｔｕｓ ｇｌｏｂｕｌｕｓ）より得られるユーカリ抽出物を有効成分として０．００１質量％〜０．１質量％含有する皮膚外用剤。
(B) Coweight containing a structural unit based on 2- (meth) acryloyloxyethyl phosphorylcholine represented by the following formula (1) and a structural unit based on alkyl (meth) acrylate represented by the following formula (2). The coalescence is 0.005% by mass to 0.5% by mass, and
(C) An external preparation for skin containing 0.001% by mass to 0.1% by mass of a eucalyptus extract obtained from Eucalyptus globulus, which is a plant belonging to the genus Eucalyptus of the Myrtaceae family, as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020004139A JP7396060B2 (en) | 2020-01-15 | 2020-01-15 | Skin external preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020004139A JP7396060B2 (en) | 2020-01-15 | 2020-01-15 | Skin external preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021109859A true JP2021109859A (en) | 2021-08-02 |
| JP7396060B2 JP7396060B2 (en) | 2023-12-12 |
Family
ID=77059083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020004139A Active JP7396060B2 (en) | 2020-01-15 | 2020-01-15 | Skin external preparations |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7396060B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023277183A1 (en) | 2021-07-01 | 2023-01-05 | 月島機械株式会社 | Method for producing crystals of bis-2-hydroxyethyl terephthalate and apparatus for producing crystals of bis-2-hydroxyethyl terephthalate |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001329482A (en) * | 2000-05-22 | 2001-11-27 | Oji Paper Co Ltd | Humectant-containing sheet product |
| JP2002322076A (en) * | 2001-02-26 | 2002-11-08 | Oji Paper Co Ltd | Trypsin inhibitor |
| JP2013177364A (en) * | 2012-02-10 | 2013-09-09 | Shiseido Co Ltd | O/w emulsified skin cosmetic |
| WO2016147992A1 (en) * | 2015-03-13 | 2016-09-22 | 日油株式会社 | Composition for nanoemulsion emulsification, bicontinuous microemulsion, cosmetic, and method for producing same |
-
2020
- 2020-01-15 JP JP2020004139A patent/JP7396060B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001329482A (en) * | 2000-05-22 | 2001-11-27 | Oji Paper Co Ltd | Humectant-containing sheet product |
| JP2002322076A (en) * | 2001-02-26 | 2002-11-08 | Oji Paper Co Ltd | Trypsin inhibitor |
| JP2013177364A (en) * | 2012-02-10 | 2013-09-09 | Shiseido Co Ltd | O/w emulsified skin cosmetic |
| WO2016147992A1 (en) * | 2015-03-13 | 2016-09-22 | 日油株式会社 | Composition for nanoemulsion emulsification, bicontinuous microemulsion, cosmetic, and method for producing same |
Non-Patent Citations (1)
| Title |
|---|
| EYE CREAM, MINTEL GNPD [ONLINE]， 2016.04，[検索日 2023.04.25], JPN6023019099, ISSN: 0005058320 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023277183A1 (en) | 2021-07-01 | 2023-01-05 | 月島機械株式会社 | Method for producing crystals of bis-2-hydroxyethyl terephthalate and apparatus for producing crystals of bis-2-hydroxyethyl terephthalate |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7396060B2 (en) | 2023-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7430666B2 (en) | Hair growth composition and method | |
| US4593046A (en) | Method of reducing skin irritation from benzoyl peroxide | |
| US5750563A (en) | Preparation for epidermis | |
| JP3053368B2 (en) | Cosmetic and method for producing the same | |
| JP6378402B1 (en) | Cosmetic composition | |
| JPH0625050B2 (en) | Aloe water and method for producing the same | |
| US20040101577A1 (en) | Composition for treating acne vulgaris and fabrication method | |
| JP7396060B2 (en) | Skin external preparations | |
| US8383166B2 (en) | Stable hydrophobic topical herbal formulationn | |
| JPH06157278A (en) | Skin external preparation for acne vulgaris | |
| CN108158938A (en) | A kind of Pimple removing scream of the ingredient containing American cockroach and preparation method thereof | |
| JP2021098655A (en) | Skin external composition | |
| JP3170700B2 (en) | Cosmetic for preventing skin aging | |
| EP2825211A1 (en) | Cosmetic composition | |
| KR20030061813A (en) | Compositions for cleansing skin and treating acne | |
| JPH11302147A (en) | Cosmetic | |
| KR100892742B1 (en) | Skin external composition for treating pimple | |
| JP6353669B2 (en) | Acne-improving composition | |
| JP2020015699A (en) | Skin cosmetics | |
| JP3190487B2 (en) | Anti-dandruff hair cosmetics and hair nourishes | |
| KR102297560B1 (en) | A Cosmetic composition comprising methyl hydrogenated rosinate | |
| KR100672247B1 (en) | Shave supplement composition | |
| JP2002060332A (en) | Cosmetic for skin | |
| JP2001329290A (en) | Cosmetic preparation | |
| JP3574107B2 (en) | External preparation for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220621 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230419 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230516 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231017 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231031 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231113 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7396060 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |